You might also like
Quest Diagnostics Incorporated is a leading provider of diagnostic information services, primarily operating through its Diagnostic Information Services (DIS) and Diagnostic Solutions (DS) segments. The company offers diagnostic insights from laboratory testing, serving a diverse clientele that includes physicians, hospitals, patients, health plans, employers, and government agencies . Additionally, Quest Diagnostics provides risk assessment services for insurers and healthcare information technology solutions for healthcare providers and payers . The company conducts most of its business in the United States but has recently expanded into the Canadian market through acquisitions .
- Diagnostic Information Services (DIS) - Provides diagnostic insights from laboratory testing, serving a wide range of customers including physicians, hospitals, patients, health plans, employers, and government agencies. This segment is characterized by a high volume of relatively low-dollar transactions, with revenues recognized primarily upon completion of the testing process .
- Diagnostic Solutions (DS) - Offers risk assessment services for insurers and healthcare information technology solutions for healthcare providers and payers. This segment includes solutions under various brands, such as:
- AmeriPath - Specializes in anatomic pathology services.
- Dermpath Diagnostics - Focuses on dermatopathology services.
- ExamOne - Provides risk assessment services for the insurance industry.
- Quanum - Delivers healthcare information technology solutions .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
James E. Davis ExecutiveBoard | Chairman, CEO, and President | None | Joined DGX in 2013. Became CEO on Nov 1, 2022, and Chairman on Apr 1, 2023. Previously held leadership roles at GE and InSightec. | View Report → |
Catherine T. Doherty Executive | Senior Vice President, Regional Businesses | None | Joined DGX in 1990. Held multiple leadership roles, including SVP of Clinical Franchise Solutions and Marketing. | |
Karthik Kuppusamy Executive | Senior Vice President, Clinical Solutions | None | Joined DGX in 2014. Oversees clinical franchises and pharmaceutical services. Formerly worked at GE Healthcare. | |
Mark A. Gardner Executive | Senior Vice President, Molecular Genomics and Oncology | None | Joined DGX in October 2022. Previously held leadership roles at Corza Medical, OmniSeq, and Thermo Fisher Scientific. | |
Mark E. Delaney Executive | Senior Vice President and Chief Commercial Officer | None | Joined DGX in March 2022. Previously held leadership roles at Hill-Rom Holdings and GE Healthcare. | |
Michael E. Prevoznik Executive | Senior Vice President and General Counsel | None | Joined DGX in 1999. Oversees legal, compliance, and governmental affairs. Previously worked at SmithKline Beecham. | |
Patrick Plewman Executive | Senior Vice President, Diagnostics Services | None | Joined DGX in 2013. Oversees data-driven analytics and services offerings. Formerly CEO of diaDexus, Inc. | |
Sam A. Samad Executive | Executive Vice President and CFO | None | Joined DGX in July 2022. Former CFO of Illumina and held senior roles at Cardinal Health and Eli Lilly. | |
Denise M. Morrison Board | Director | Board Member at MetLife, Inc. and Visa, Inc.; Founder of Denise Morrison & Associates | Joined DGX board in 2019. Former CEO of Campbell Soup Company. | |
Gary M. Pfeiffer Board | Director | None | Joined DGX board in 2004. Former CFO of DuPont and Secretary of Finance for Delaware. | |
Luis A. Diaz, Jr. Board | Director | Head of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center | Joined DGX board in 2023. Renowned oncologist known for pioneering work in cancer biomarkers and immunotherapy. | |
Robert B. Carter Board | Director | Board Member at New York Life; Trustee at University of Memphis | Joined DGX board in May 2024. Former CIO of FedEx Corporation. | |
Timothy L. Main Board | Director | Non-Executive Chairman of WNS (Holdings) Limited | Joined DGX board in 2014. Extensive experience in capital markets, technology, and corporate governance. | |
Timothy M. Ring Board | Lead Independent Director | Board Member at Becton, Dickinson and Company; Co-founder of TeamFund, Inc. | Joined DGX board in 2011. Former CEO of C.R. Bard, Inc. | |
Tracey C. Doi Board | Director | Board Member at Pentair plc; Trustee at SunAmerica Series Trust and Season Series Trust | Joined DGX board in 2021. Former CFO of Toyota Motor North America. | |
Vicky B. Gregg Board | Director | Cofounder of Guidon Partners LLC; Board Member at Acadia Healthcare and Erlanger Health System | Joined DGX board in 2014. Former CEO of BlueCross BlueShield of Tennessee. | |
Wright L. Lassiter III Board | Director | CEO of CommonSpirit Health; Board Member at Fortive Corporation | Joined DGX board in 2020. Former CEO of Henry Ford Health System. |
- With COVID-19 revenues becoming insignificant and impacting growth by only about 50 basis points , how does Quest plan to compensate for this decline and maintain or accelerate organic growth going forward?
- Considering that M&A contributed approximately 4% to revenue growth in the quarter and that LifeLabs alone added about $70 million , is the company's growth overly reliant on acquisitions, and what risks do you see in integrating multiple acquisitions, especially in new markets like Canada?
- As you expand into new geographies where health systems previously limited your reach , what challenges do you anticipate in gaining market share in these areas, and how might this affect pricing and relationships with local providers?
- Given the anticipated increase in interest expense due to recent debt issuance and the plan to retire lower coupon senior notes in 2025 , how will this higher interest burden impact your margins and ability to invest in growth initiatives?
- With the dilution from the Haystack MRD acquisition being approximately $0.20 this year and expected improvements next year , can you detail when you expect this investment to become accretive and what is the plan if reimbursement does not meet expectations?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The largest commercial clinical laboratory competitor in the diagnostic information services industry, competing primarily in the fragmented and highly competitive clinical testing market. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
OhioHealth | 2024 | Quest Diagnostics acquired select assets from OhioHealth in an all‐cash deal valued at $200 million, completed on October 13, 2024; the deal expands cost-effective laboratory services with a shift of outreach testing to Quest’s Pittsburgh facility while preserving OhioHealth’s hospital lab operations. |
Three Physician Groups in New York | 2024 | Quest Diagnostics completed an all‐cash transaction for $300 million to acquire the laboratory business of three New York-based physician groups, integrating $243 million in goodwill and $57 million in customer-related intangible assets into its Diagnostic Information Services business to strengthen its regional presence. |
Allina Health | 2024 | The acquisition of select assets from Allina Health’s outreach laboratory services was executed as an all‐cash transaction for $230 million, incorporating $55 million in customer-related intangible assets and $175 million in goodwill, aimed at expanding high-quality lab services in Minnesota and western Wisconsin within Quest’s DIS segment. |
LifeLabs Inc. | 2024 | Quest Diagnostics acquired LifeLabs Inc. for approximately CAN $1.35 billion (around USD $1 billion) by combining cash on hand with proceeds from a $1.85 billion senior notes offering, with the deal expected to enhance diagnostic innovation in Canada while preserving LifeLabs’ brand and management team. |
PathAI Diagnostics | 2024 | Completed on June 10, 2024, this all‐cash acquisition for $100 million involved acquiring select assets including $55 million of tax-deductible goodwill and customer-related intangibles, with efforts to rebrand the Memphis laboratory as Quest’s national AI/digital R&D center to support enhanced pathology services. |
Lenco Diagnostic Laboratories, Inc. (Lenco) | 2024 | In an all‐cash transaction valued at $111 million on February 12, 2024, Quest Diagnostics acquired Lenco Diagnostic Laboratories, integrating $75 million of tax-deductible goodwill and $43 million in customer-related intangible assets, thereby strengthening its Diagnostic Information Services services in New York. |
Haystack Oncology, Inc. | 2023 | Quest Diagnostics’ acquisition of Haystack Oncology, completed on June 20, 2023, was an all‐cash transaction for $392 million (with additional contingent payments up to $150 million based on revenue targets and CMS milestones), aimed at bolstering its capabilities in minimal residual disease testing and liquid biopsy technology with significant goodwill and technology-related intangible assets acquired. |
New York-Presbyterian Laboratory Services | 2023 | The company acquired select assets of New York-Presbyterian’s laboratory services on April 17, 2023, in an all‐cash deal for $275 million, which included $222 million of tax-deductible goodwill and $53 million in customer-related intangible assets, integrating the business into its Diagnostic Information Services segment to expand its health system partnerships. |
Pack Health, LLC | 2022 | Acquired on February 1, 2022, for a net transaction value of $123 million (comprising $105 million cash and $18 million contingent on future revenues), the deal enhanced Quest Diagnostics’ extended care capabilities by integrating a patient engagement platform, with significant goodwill and intangible asset components recognized under the acquisition method. |
Recent press releases and 8-K filings for DGX.
- Q1 2025 revenue reached $2.65 billion, up 12.1% year-over-year, reflecting robust quarterly performance .
- Reported diluted EPS of $1.94 (up 12.8% YoY) and adjusted EPS of $2.21, underscoring strong operational performance .
- Reaffirmed full-year guidance with expected revenues between $10.7B and $10.85B and EPS guidance of reported diluted EPS between $8.62 and $8.87 plus adjusted diluted EPS between $9.55 and $9.80 .
- Strategic investments in advanced diagnostics—including tests like PFAS forever chemicals, Haystack MRD, and an AD-Detect panel for Alzheimer’s—are fueling growth .
- Operational enhancements through automation, robotics, and AI are boosting quality and productivity .
- A robust M&A pipeline complemented by strategic acquisitions, enterprise account growth, and favorable regulatory developments (e.g., the court decision on FDA LDT rule) is driving further expansion .
- Quest Diagnostics announced the launch of its new AD-Detect™ blood test, which confirms Alzheimer’s pathology in patients with mild cognitive impairment or dementia using proprietary tandem mass spectrometry and immunoassay techniques.
- The test demonstrated over 90% sensitivity and specificity with positive and negative predictive values of 89% in a real-world heterogeneous population, offering a less invasive and more affordable alternative to PET imaging and lumbar puncture.
- The expansive network of nearly 8,000 patient access points supports broad adoption, excluding only New York where clinical approval is pending.
- Investor Day Overview: The event detailed Quest Diagnostics’ commitment to sustainable growth by addressing market trends such as rising obesity and evolving disease diagnostic needs, setting the stage for strategic operational improvements.
- Diagnostic Innovation: Executives highlighted investments in advanced clinical solutions, including enhanced blood-based testing, AI-driven digital pathology, and automation initiatives designed to drive above‐average growth in key clinical areas.
- Operational Transformation: The company is modernizing its order-to-cash process through Project Nova and expects to achieve 3% annual productivity savings by standardizing, simplifying, and digitizing its processes, further enhancing customer and employee experience.
- Financial and M&A Outlook: With reaffirmed 2025 guidance of approximately $10.78 billion in revenue and $9.68 EPS, Quest Diagnostics also outlined long-term targets of 4-5% revenue CAGR and 7-9% adjusted EPS CAGR, supported by disciplined M&A activities and strategic regional consolidations.
- Growth Outlook: The company presented a long-term strategy targeting 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR beyond 2025, underpinned by operational improvements and investments in advanced diagnostics.
- Expansion and Acquisitions: Quest highlighted the completion of several key acquisitions in 2024 expected to generate approximately $1 billion in annualized revenue, enhancing its reach in the hospital and physician channels.
- Innovative Market Positioning: The presentation emphasized leveraging technological innovations such as AI and automation to capitalize on strong market trends in both the US and Canadian lab sectors, driving above-market, double-digit growth in key clinical areas.
- Long-term growth outlook reaffirmed: The company projects 4-5% revenue CAGR and 7-9% adjusted EPS CAGR beyond 2025, driven by strategic investments in advanced diagnostics, automation, and IT modernization initiatives such as Project Nova.
- Full year 2025 guidance confirmed: Net revenues are expected to range between $10.70 billion and $10.85 billion, although first-quarter headwinds from adverse weather may impact revenue by approximately $25 million and EPS by $0.10.
- Focused expansion across key channels: Quest Diagnostics is actively enhancing its presence in the physician and hospital channels with initiatives aimed at increasing market access and operational productivity.
- Revenue & EPS Guidance: The company announced 2025 guidance with revenue expected between $10.70B and $10.85B and adjusted EPS between $9.55 and $9.80, with midpoints reflecting approximately +9.1% revenue and +8.3% EPS growth year-over-year.
- Long-Term Growth Outlook: Beyond 2025, the outlook targets 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR, underpinned by substantial investments including Project Nova to modernize the order-to-cash process.
- Operational Improvements: A key focus is on enhancing quality, productivity, and customer experience through initiatives like Invigorate, targeting around 3% in annual cost savings and productivity improvements using streamlined processes and technology upgrades.
- Capital Deployment Strategy: The company emphasizes a balanced capital deployment approach, having consistently reinvested in its business while returning the majority of free cash flow to shareholders through dividends and share repurchases.
- Long-term outlook: The company projects revenue growth at 4-5% CAGR and adjusted EPS growth at 7-9% CAGR beyond 2025.
- Full year 2025 guidance reaffirmed with detailed revenue and earnings targets, noting a Q1 headwind from adverse weather.
- Strategic initiatives include expanding its physician and hospital channels and driving double-digit growth in advanced diagnostics across key clinical areas.
- Technology investments such as increased automation, robotics, AI initiatives, and the launch of Project Nova aim to modernize IT infrastructure and reduce costs.